Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11208MR)

This product GTTS-WQ11208MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11208MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14474MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ7872MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ510MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ9183MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ2272MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ285MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ14797MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ1759MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW